Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUILIBRIX-S: VMX-C001 vs usual pharmacological care in FXa DOAC-treated patients requiring urgent high-bleeding-risk procedures
jRCT2071260038Phase 3Recruiting
- Sponsor
- VarmX
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of VMX-C001 in None (2 arms), sponsored by VarmX. Primary endpoint: Haemostatic efficacy during required procedure. Started Jun 2026; status: recruiting.
02
Drugs
VMX-C001
Beyond the preview
Go deeper on jRCT2071260038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260038.